[A multi-center observation of the therapeutic efficacy of Bencycloquidium bromide in the treatment of seasonal allergic rhinitis with predominant symptoms of rhinorrhea].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lin chuang er bi yan hou tou jing wai ke za zhi bain ji bu Country of Publication: China NLM ID: 101303164 Publication Model: Print Cited Medium: Print ISSN: 2096-7993 (Print) Linking ISSN: 20967993 NLM ISO Abbreviation: Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Subsets: MEDLINE
    • Publication Information:
      Original Publication: Wuhan Shi : Lin chuang er bi yan hou tou jing wai ke za zhi bain ji bu
    • Subject Terms:
      Rhinitis, Allergic, Seasonal*/drug therapy ; Rhinitis, Allergic*/drug therapy; Male ; Female ; Humans ; Adult ; Nasal Sprays ; Quality of Life ; Administration, Intranasal ; Rhinorrhea ; Double-Blind Method ; Treatment Outcome
    • Abstract:
      Objective: To observe the efficacy and safety of the M receptor antagonist Bencycloquidium bromide nasal spray in treatment of seasonal allergic rhinitis with runny nose as the main symptom. Methods: From August 2021 to September 2021, 134 patients with seasonal allergic rhinitis were enrolled in the otolaryngology Outpatient Department of Peking University Third Hospital, First Affiliated Hospital of Harbin Medical University and China-Japanese Friendship Hospital of Jilin University, including 71 males and 63 females, with a median age of 38 years. TNSS score and visual analogue scale（VAS） of total nasal symptoms were observed during 2 weeks of treatment with Bencycloquidium bromide nasal spray. Results: TNSS score decreased from （8.89±3.31） on day 0 to （3.71±2.51） on day 14（ P <0.001）, VAS score of nasal symptoms decreased from （24.86±7.40） on day 0 to （6.84±5.94） on day 14（ P <0.001）, VAS score of rhinorrhoea decreased from （6.88±2.06） on day 0 to （1.91±1.81） on day 14（ P <0.001）. Rhinoconjunctivitis quality of life questionnaire（RQLQ） score decreased from （94.63±33.35） on day 0 to （44.95±32.28） on day 14（ P <0.001）. The incidence of adverse reaction was low and no serious adverse events occurred during the whole experiment. Conclusion: Bencycloquidium bromide nasal spray has significant efficacy and good safety in the treatment of seasonal allergic rhinitis.
      Competing Interests: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
      (Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.)
    • References:
      Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Nov;35(11):1004-1008. (PMID: 34886604)
      Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Dec;35(12):1124-1129. (PMID: 34886629)
      Respir Res. 2010 Nov 26;11:163. (PMID: 21110834)
      Regul Toxicol Pharmacol. 2011 Mar;59(2):343-52. (PMID: 21130130)
      Ann Allergy Asthma Immunol. 1999 Apr;82(4):349-59. (PMID: 10227333)
      World Allergy Organ J. 2023 Mar 26;16(3):100744. (PMID: 37008533)
      Allergy. 2018 Sep;73(9):1784-1791. (PMID: 29624710)
      J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3. (PMID: 31627910)
      Drugs R D. 2012 Mar 1;12(1):17-28. (PMID: 22339483)
      Eur Arch Otorhinolaryngol. 2020 Nov;277(11):3067-3077. (PMID: 32623510)
      Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Sep 05;31(17):1330-1333. (PMID: 29798224)
      Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Feb 7;57(2):106-129. (PMID: 35078291)
      Postepy Dermatol Alergol. 2019 Jun;36(3):255-260. (PMID: 31333340)
      Respir Res. 2011 Jul 15;12:95. (PMID: 21831329)
    • Contributed Indexing:
      Keywords: allergic rhinitis; cholinergic antagonists; nasal sprays
      Local Abstract: [Publisher, Chinese] 目的： 多中心观察M受体拮抗剂苯环喹溴铵鼻喷雾剂治疗以流涕为主要症状的季节性变应性鼻炎（SAR）患者的疗效及安全性。 方法： 纳入2021年8月-2021年9月北京大学第三医院、吉林中日联谊医院、哈尔滨医科大学附属第一医院耳鼻喉科门诊以流涕为主的SAR患者134例，其中男71例，女63例，中位年龄38岁。用苯环喹溴铵鼻喷雾剂治疗，4次/d，每次2喷90 μg，用药14 d后，观察疗效及安全性。 结果： 受试者鼻部症状TNSS评分由第0天的（8.89±3.31）分下降至（3.71±2.51）分（ P <0.001），鼻部总症状VAS评分由第0天的（24.86±7.40）分下降至用药第14天的（6.84±5.94）分（ P <0.001），流涕症状VAS评分由第0天的（6.88±2.06）分下降至用药第14天的（1.91±1.81）分（ P <0.001），鼻结膜炎生存质量调查问卷评分由第0天的（94.63±33.35）分下降至用药第14天的（44.95±32.28）分（ P <0.001），整个试验过程中无严重不良事件发生。 结论： M受体拮抗剂苯环喹溴铵鼻喷雾剂对季节性变应性鼻炎具有显著的疗效和良好的安全性。.
    • Accession Number:
      0 (bencycloquidium bromide)
      0 (Nasal Sprays)
    • Publication Date:
      Date Created: 20230807 Date Completed: 20230809 Latest Revision: 20240926
    • Publication Date:
      20240926
    • Accession Number:
      PMC10570111
    • Accession Number:
      10.13201/j.issn.2096-7993.2023.07.008
    • Accession Number:
      37549947